Displaying results 1 - 12 of 54
Relaunch of the MEP Friends of the Liver Group On-demand Webinar • Liver disease is now the leading cause of years of working life lost in Europe, after ischaemic heart disease. Liver diseases are generally avoidable or treatable if measures for prevention and early detection are properly implemented; achieving this would reduce premature morbidity and mortality, saving the lives of almost 300’000 people across Europe each year. The European Association for the Study of the Liver (EASL) is relaunching an interest group to raise awareness, put liver health higher on the political agenda and make policy recommendations.
Metabolism, Alcohol & Toxicity
Non-alcoholic fatty liver disease: A patient guideline • This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. Click here to download the short version and here to download the publication in PDF format. EASL NAFLD-NASH Patient Guideline Short Version Non-alcoholic fatty liver disease: A patient guideline
EASL Studio S3 E6: How to improve end-of-life care in liver disease? • Description In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines: When is the best time to think about end-of-life care in liver disease? What does it mean for the liver care team? When and how should patients be referred to specialised palliative care? Faculty Dr Patrizia Künzler-Heule (Moderator) Prof. Philip Larkin (Faculty) Dr Philip Berry (Faculty) ℹ️ Please click here to access the podcast version of this EASL Studio episode.
EASL Studio Podcast S3 E6: How to improve end-of-life care in liver disease? • Description In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines: When is the best time to think about end-of-life care in liver disease? What does it mean for the liver care team? When and how should patients be referred to specialised palliative care? Faculty Dr Patrizia Künzler-Heule (Moderator) Prof. Philip Larkin (Faculty) Dr Philip Berry (Faculty) Listen to the podcast
ILC 2021 Takeaways – Public health • As part of the International Liver Congress (ILC) 2021, the EASL Takeaways take a look at key topics from the congress, with leading experts discussing the most impactful science and putting it into perspective. This session, presented by Professors Maria Buti, Shira Zelber-Sagi and Antonio Craxì, explores prominent themes from ILC 2021 on the topic of public health. Professor Zelber-Sagi takes the panel through the importance of public health policies in tackling obesity, particularly in populations with low socioeconomic status. They examine the associations between food insecurity and all-cause mortality in adults with liver disease, between parental pre-pregnancy BMI and offspring NAFLD, and between obesity and loss to follow-up in cirrhotic populations. The panel then reviews the impact of the COVID-19 pandemic on liver care, as well as the effect of liver disease on COVID-19 mortality. Finally, Professor Craxì discusses residual mortality in HBV carriers and the effects of HBV vaccines on liver cancer prevention.
COVID-19 and the liver
Ask EASL: podcast on COVID-19 vaccination in patients with liver disease • Ask EASL is an ongoing series of educational podcasts dedicated to answering questions from patients and patient organisations on important topics around liver disease. In this episode, Professor Markus Cornberg is joined by Dr Christiane Eberhardt and Professor Daniel Shouval to answer a range of questions raised by EASL’s Patient Synergies regarding the recently approved COVID-19 vaccinations. They address topics including the reasons for the rapid development of the vaccines, whether immunocompromised liver transplant patients should receive the vaccine, real-world data from vaccination programmes worldwide and the potential duration of immunity.
Ask EASL: podcast on Liver Cancer • Ask EASL is a new series of educational content dedicated to answering questions from patients and patient organisations on important topics around liver disease. In this audio interview conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.
EASL Studio S1 E1: Liver Cancer Awareness Month • Description Since 2020 EASL Studio has been a part of the International Liver Congress (ILC), bringing you the most up-to-date research live from the congress. But EASL Studio is evolving. EASL Studio is now a new platform through which we will be exploring hepatology every week, from every angle. Through live debates, interviews, and roundtable discussions, EASL Studio will be a chance to peak behind the scenes. Hear the expert’s opinion on the latest research. Discover what it’s like to be a young investigator. Meet the Nurses, the allied health professionals, and the patients they work with. Watch on-demand the first Session that was broadcasted on Wednesday 27 October 2021. Programme Time Title 00:00-04:12 Welcome and Introductions Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain 04:12-28:26 Topic 1: Raising awareness about Liver Cancer Nathalie Ganne-Carrié, Avicenne Hospital, France Peter Jepsen, University of Aarhus, Denmark 28:26-47:34 Topic 2: Liver Cancer Summit: Highlights from 2021 and what awaits us in 2022 Angela Lamarca, University of Manchester, United Kingdom Jean-Charles Nault, Avicenne Hospital, France 47:34-50:31 Closing remarks Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain
EASL Studio Special Edition: Highlights of Liver Cancer Summit 2022 • Description The highlights of EASL's Liver Cancer Summit 2022 - What is practice changing right now and where are the current controversies? How do our experts interprete the new data on Immunotherapy in HCC and CCA, and what to expect in 2022: Upcoming trials, New combinations, New biomarkers Watch on-demand the session that was broadcast Friday 4 February 2022.
EASL Studio Special Edition: Live from Viral Hepatitis Elimination Conference 2022 • Description The WHO goal of eliminating viral hepatitis by 2030 has led to a surge in activities to achieve a world free from viral liver disease. What steps must be taken? How do you define sustainable elimination? Listen to the experts debriefing the Viral Hepatitis Elimination Conference 2022. Discover the highlights of the conference and learn more about what successful countries have done to achieve viral hepatitis elimination.
EASL Policy Dialogues Episode 1: Drug use, viral hepatitis, and Europe • Description In this first episode, the experts are discussing the multifaceted issue of drug use in relation to the hepatitis C elimination in Europe. How far are we from hepatitis C elimination in Europe? How are drug use and hepatitis C issues related? How can the work of the European Parliament contribute to eliminating hepatitis?